In the periphery, combination therapy elicited a significant EMT6 tumor-specific IFNγ response (Fig. 4b, day 21), sustained 6 days after treatment cessation (Fig. 4c, day 25); both correlated with tumor size reduction (Fig. 4d). The gene discussed is IFNG; the disease is neoplasm.